SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-15-010204
Filing Date
2015-11-09
Accepted
2015-11-09 16:53:48
Documents
11
Period of Report
2015-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q navb-10q_20150930.htm 10-Q 1493134
2 EX-31.1 navb-ex311_188.htm EX-31.1 9865
3 EX-31.2 navb-ex312_189.htm EX-31.2 9938
4 EX-32.1 navb-ex321_190.htm EX-32.1 5180
5 EX-32.2 navb-ex322_191.htm EX-32.2 5186
  Complete submission text file 0001564590-15-010204.txt   6143232

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT navb-20150930.xml EX-101.INS 1218566
7 XBRL TAXONOMY EXTENSION SCHEMA navb-20150930.xsd EX-101.SCH 50120
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20150930_cal.xml EX-101.CAL 45637
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20150930_def.xml EX-101.DEF 185031
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20150930_lab.xml EX-101.LAB 421770
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20150930_pre.xml EX-101.PRE 327205
Mailing Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017
Business Address 5600 BLAZER PARKWAY SUITE 200 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 151216403
SIC: 2835 In Vitro & In Vivo Diagnostic Substances